# Expression Analysis of VEGF-Related Hub Genes and Pathways in Breast Cancer: A Comprehensive Bioinformatics Analysis

**Authors:** Mohadeseh Khoshandam, Mohammad Rahmanian, Mohammad Taghi Hedayati Goudarzi, Hossein Soltaninejad, Sadegh Babashah, Mahdiye Khoshandam

PMC · DOI: 10.30476/ijms.2025.106542.4074 · Iranian Journal of Medical Sciences · 2026-02-01

## TL;DR

This study identifies key genes and pathways related to VEGF in breast cancer, suggesting potential targets for treatment.

## Contribution

The study provides new insights into VEGF-related hub genes and pathways in breast cancer using comprehensive bioinformatics methods.

## Key findings

- MMP9, MMP14, and VEGFA showed significant increases in expression in breast cancer.
- Key pathways like receptor binding signaling and extracellular matrix regulation were enriched among differentially expressed genes.
- Validation through microarray studies confirmed significant gene expression changes in breast cancer datasets.

## Abstract

Breast cancer is the most common form of cancer among women worldwide, and the rates of both new cases and deaths have increased over the past two decades. The aim of the study was to identify and validate molecular pathways that could potentially be targeted for therapeutic interventions.

The bioinformatics resource WebGestalt was used to determine the functional annotation of the Gene Ontology, as well as enrichment analysis of Reactome and KEGG pathways in 2023-2024. GeneMANIA, a server for assessing protein-gene interactions, co-localization, pathways, co-expression, and protein-domain similarity of target genes and their interacting genes, was evaluated via this web tool. GEO was also used to determine mRNA expression levels in BRCA individuals. R packages were used to screen for differentially expressed genes for both datasets. On the other hand, the open cancer resources GENT2 TNMPlot, UCSCXena, ENCORI platform, BioXpress, OncoDB, OncoMX, and GEPIA2 were used to measure the differential expression of mRNAs in BRCA patients.

Among the genes analyzed, matrix metalloproteinase-9 (MMP9) showed the greatest change. Similarly, matrix metallopeptidase 14 (MMP14) and Endogenous
Vascular Endothelial Growth Factor-A (VEGFA) showed significant increases. Other up-regulated genes, including Apolipoprotein E (APOE),
Hypoxia-Inducible Factor-1 Alpha (HIF1A), and Tumor Necrosis Factor (TNF) showed minimal expression changes with minor fluctuations.
Finally, Interleukin-1 alpha precursor (IL1A) exhibited a slight increase in expression. Validation of gene expression changes through microarray studies on
the GSE37751 and GSE42568 datasets provided consistent and significant results for several of the studied genes. GO analysis further revealed significant molecular functions,
cellular components, KEGG pathways, and biological processes that were enriched among the differentially expressed genes. Among the top pathways identified based on FDR and P value were
receptor binding signaling, regulation of cell migration, the extracellular matrix, and the AGE-RAGE signaling pathway.

The results predict that the hub genes correlated with angiogenesis may serve as potential therapeutic targets or could be biomarkers for breast cancer.

## Linked entities

- **Genes:** MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], APOE (apolipoprotein E) [NCBI Gene 348], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], TNF (tumor necrosis factor) [NCBI Gene 7124], IL1A (interleukin 1 alpha) [NCBI Gene 3552]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, Tafazzin (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 66826] {aka 5031411C02Rik, 9130012G04Rik, G4.5, Taz}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, Mmp14 (matrix metallopeptidase 14 (membrane-inserted)) [NCBI Gene 17387] {aka MMP-X1, MT-MMP-1, MT1-MMP, sabe}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, MOK (MOK protein kinase) [NCBI Gene 5891] {aka RAGE, RAGE-1, RAGE1, STK30}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CHUK (component of inhibitor of nuclear factor kappa B kinase complex) [NCBI Gene 1147] {aka BPS2, IKBKA, IKK-1, IKK-alpha, IKK1, IKKA}
- **Diseases:** Breast Cancer (MESH:D001943), hypoxia (MESH:D000860), solid (MESH:D018250), Bladder cancer (MESH:D001749), atherosclerosis (MESH:D050197), diabetic complications (MESH:D048909), metastasis (MESH:D009362), Rheumatoid arthritis (MESH:D001172), melanomas (MESH:D008545), inflammation (MESH:D007249), cytotoxic (MESH:D064420), endocrine disorders (MESH:D004700), Tumors (MESH:D009369), lung cancer (MESH:D008175)
- **Chemicals:** lipid (MESH:D008055), LPS (MESH:D008070), steroid (MESH:D013256), ROS (MESH:D017382), acylglycerol (MESH:D005989), glucose (MESH:D005947), oxygen (MESH:D010100), triglyceride-rich lipoprotein (-), vemurafenib (MESH:D000077484), amino acid (MESH:D000596), paclitaxel (MESH:D017239)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** BRAFV600E

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929908/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929908/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929908/full.md

---
Source: https://tomesphere.com/paper/PMC12929908